Schrodinger, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SDGR in the last 7 days.
No SEC Form 4 filings for $SDGR in the last 30 days.
See all $SDGR insider activity →Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
FactSet-reported analyst estimates show Schrodinger, Inc. (SDGR) average 12-month price target increased to $21.83 from $20.57. Targets range from $17 to $30. Based on the Aug. 13 close, the update implies about 18% upside. The consensus rating remains “Buy” among 6 analysts (5 Buys, 1 Hold, 0 Sells).
Investing.com reports Cathie Wood’s ARK ETFs published Thursday trades. ARK bought 106,941 shares of Cerebras Systems (CBRS) for about $28.0M and bought Securitize (SECZ) and Perceptive Capital Solutions (FRNM). It sold Shopify (SHOP) 57,045 shares for about $8.6M and sold Palantir (PLTR) for about $7.5M, plus other smaller trades.
Recent SDGR coverage spans financial news, sector analysis and corporate actions.
Reported restructuring costs can pressure near-term earnings optics while indicating operational streamlining.
PT increase signals incremental bullish sell-side sentiment, but it is not a new company fundamental disclosure.
The purchase may be a mild sentiment tailwind for SDGR, but the article lacks any new SDGR catalyst.
The earnings swing and BMS deployment of Bunsen reinforce the embedded-AI adoption thesis, but the shelf filing adds dilution overhang.
SDGR is positioned as an execution leader with concrete operating metrics and a product-timeline catalyst.
alphai scores every news story that mentions SDGR with an AI model for sentiment and relevance, and aggregates insider trades from Schrodinger, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readFactSet-reported analyst estimates show Schrodinger, Inc. (SDGR) average 12-month price target increased to $21.83 from $20.57. Targets range from $17 to $30. Based on the Aug. 13 close, the update implies about 18% upside. The consensus rating remains “Buy” among 6 analysts (5 Buys, 1 Hold, 0 Sells).
1 min readInvesting.com reports Cathie Wood’s ARK ETFs published Thursday trades. ARK bought 106,941 shares of Cerebras Systems (CBRS) for about $28.0M and bought Securitize (SECZ) and Perceptive Capital Solutions (FRNM). It sold Shopify (SHOP) 57,045 shares for about $8.6M and sold Palantir (PLTR) for about $7.5M, plus other smaller trades.
3 min readSchrödinger (SDGR) reported Q2 2026 revenue of $58.89M, turning from a prior-year loss to net income of $5.98M, and filed a $46.95M shelf registration for 3,000,000 shares tied to its ESOP. Bristol Myers Squibb said it will deploy Schrödinger’s agentic AI co-scientist Bunsen across its research organization, expanding their collaboration.
6 min readAnthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.
6 min readSimply Wall St reports Schrödinger (SDGR) shifted from a loss to a profit in its latest quarterly results and announced an AI-focused deal with Bristol Myers Squibb. The article cites SDGR shares up 22.84% over 7 days and 47.91% over 90 days. It also presents a “fair value” of $20.88 versus a $18.77 close and assumes 11.1% annual revenue growth.
6 min readSchrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Second Quarter 2026 Financial Results Second Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery New York, August 5, 2026 – Schrödinger, Inc. (Nasdaq: S
6 min readSchrodinger, Inc. (SDGR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. sdgr-20260622 1540 Broadway 24th Floor New York NY FALSE 0001490978 0001490978 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT P
3 min readSchrodinger, Inc. (SDGR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exhibit101-mannixaklianxse.htm EX-10.1 Document Exhibit 10.1 TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation, and Release of Claims Agreement (the “ Agreement ”) is entered into by and between Schrödinger, Inc. (the “ Company ”) and M
3 min readThe article compares Recursion Pharmaceuticals (RXRX) and Schrödinger (SDGR) as digital drug-discovery platforms. Recursion reported FY2025 revenue of about $74.7M (+26.9%) and a net loss of about $644.8M, with negative free cash flow of about $378.3M and a debt-to-equity ratio near 0.1x. Schrödinger posted FY2025 revenue of about $255.9M (+23.3%), net loss about $103.3M, and free cash flow about $12.5M.
7 min read
